CAR-T Tx Shifts into First Gear in Lung Cancer
laurabbook@gmail.com2019-09-25T15:24:37-07:00*October 2018* by Shalmali Pal Medpage Today and ASCO Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early
25
September 2019
25
September 2019
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity
laurabbook@gmail.com2019-09-25T15:17:16-07:00*August 2019* Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing
12
August 2019
In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer
laurabbook@gmail.com2019-08-12T16:38:39-07:00*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and
12
August 2019
Are BiTE Antibodies The Next Treatment for EGFR + NSCLC?
laurabbook@gmail.com2019-08-12T16:21:40-07:00*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. BiTE antibodies are showing promise as a potential new treatment option for those
17
July 2019
Video: Intro to EGFR Mutation in Lung Cancer | Hope With Answers
laurabbook@gmail.com2019-07-17T12:00:06-07:00Understand the EGFR mutation in lung cancer through this discussion between Dr. Natasha Leighl of Princess Margaret Hospital in Toronto
6
July 2019
Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow
laurabbook@gmail.com2019-07-06T12:03:57-07:00The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR
18
June 2019
Warning: Using Osimertinib After Immunotherapy
laurabbook@gmail.com2019-06-18T15:40:47-07:00*June 2019* Medscape. The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events)
18
June 2019
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients
laurabbook@gmail.com2019-06-18T15:25:17-07:00*January 2019* Lung Cancer. This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and
17
March 2019
Deep Dive: Brigatinib + Cetuximab Combo for Triple-Mutant EGFR
laurabbook@gmail.com2019-03-17T11:39:10-07:00*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of
17
March 2019
Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance
laurabbook@gmail.com2019-03-17T11:10:16-07:00*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the